An updated review of AstraZeneca’s coronavirus vaccine showed the jab is 76% effective against the illness, downgraded from the 79% reported in earlier tests, which US health officials said were based on “outdated” information.
The pharma firm publicized the results of its 32,000-person US trial in the early hours of Thursday morning, reporting that the immunization is 76% effective overall and 100% effective in staving off “critical disease and hospitalization” from Covid-19. For adults over the age of 65, the company put the figure at 85%.
The new results come after US health officials publicly chided AstraZeneca for basing trial results it reported earlier this week on “outdated information,” saying the company may have presented an “incomplete view of the efficacy data.” The US National Institute of Allergy and Infectious Diseases (NIAID) urged the firm to work with regulators to review the results and “ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”
While the review published on Thursday found that “the vaccine was well tolerated, and no safety concerns related to the vaccine were identified” during the trial, the new data follows a flurry of reports in Europe and elsewhere of adverse reactions among recipients of the inoculation, many involving blood clots. At least 17 countries suspended their rollout of the AstraZeneca jab amid those reports, though several have since resumed after EU health authorities declared the vaccine safe and not related to the clotting issues, which in some cases were fatal.
However, a research team from Germany’s Greifswald University Hospital claimed last week to have found a link between the vaccine and blood clots, also known as “vein thrombosis.” The researchers said an immune response to the jab could lead to the formation of antibodies that are normally stimulated when an organism needs to heal a wound through blood coagulation, potentially creating blood clots, particularly in the brain.
Around the same time, the World Health Organization said it was still unknown whether the AstraZeneca vaccine could cause “very rare and unique thromboembolic events,” noting that a clear “causal relationship” was still not established. The WHO nonetheless concluded the jab has a “positive benefit-risk profile.”
With the AstraZeneca vaccine still awaiting emergency-use authorization in the US, the new, slightly less promising data released on Thursday could mark a setback for the company, especially amid ongoing fallout from weeks of bad press in Europe. A separate controversy erupted on the continent this week after France accused the company of failing to meet its vaccine delivery commitments, with government spokesman Gabriel Attal calling the situation “completely unacceptable.” In response, AstraZeneca insisted it was fulfilling its obligations, and that its deal with the EU merely requires it to make the “best reasonable efforts” to distribute the immunization.
Think your friends would be interested? Share this story!
An updated review of AstraZeneca’s coronavirus vaccine showed the jab is 76% effective against the illness, downgraded from the 79% reported in earlier tests, which US health officials said were based on “outdated” information. Read Full Article at RT.com Read More
I hate to snuff out any post-Independence Day fervor that you still might be enjoying. Oh, well. “Wet Blanket” is my middle name. All the annual Old Glory-waving rituals and public displays of patriotic affection can’t change this bitter fact: Our once-sovereign nation has become nothing more than a morbidly obese cash cow for what […]
The political jargon and posturing one hears these days seems to suggest that we are in an era unlike any that has ever occurred before. Hope springs anew, there is light at the end of the tunnel, politicians gush, and for those of our elites who really want to impress with their knowledge of history, […]
Story at-a-glance The vast majority of the world’s assets are owned by just two investment firms — BlackRock and the Vanguard Group. Combined, they have ownership in nearly 90% of all S&P 500 firms, and through their investment holdings they secretly wield monopoly control over all industries By now you may be familiar with the […]
